Skip to main content
SpringerLink
Log in

Immune checkpoint inhibitors and pre-existing antinuclear antibodies: the rheumatologist point of view

  • Correspondence
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Karimian Z, Mavoungou S, Salem JE, Tubach F, Dechartres A. The quality of reporting general safety parameters and immune-related adverse events in clinical trials of FDA-approved immune checkpoint inhibitors. BMC Cancer. 2020;20:1128.

    Article  Google Scholar 

  2. Le Burel S, Champiat S, Mateus C, Marabelle A, Michot JM, Robert C, Belkhir R, Soria JC, Laghouati S, Voisin AL, Fain O, Mékinian A, Coutte L, Szwebel TA, Dunogeant L, Lioger B, Luxembourger C, Mariette X, Lambotte O. Prevalence of immune-related systemic adverse events in patients treated with anti-programmed cell death 1/anti-programmed cell death-ligand 1 agents: a single-centre pharmacovigilance database analysis. Eur J Cancer. 2017;82:34–44.

    Article  Google Scholar 

  3. Lidar M, Giat E, Garelick D, Horowitz Y, Amital H, Steinberg-Silman Y, Schachter J, Shapira-Frommer R, Markel G. Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors. Autoimmun Rev. 2018;17:284–9.

    Article  CAS  Google Scholar 

  4. Buder-Bakhaya K, Benesova K, Schulz C, Anwar H, Dimitrakopoulou-Strauss A, Weber TF, Enk A, Lorenz HM, Hassel JC. Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies. Cancer Immunol Immunother. 2018;67:175–82.

    Article  CAS  Google Scholar 

  5. Belkhir R, Burel SL, Dunogeant L, Marabelle A, Hollebecque A, Besse B, Leary A, Voisin AL, Pontoizeau C, Coutte L, Pertuiset E, Mouterde G, Fain O, Lambotte O, Mariette X. Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment. Ann Rheum Dis. 2017;76:1747–50.

    Article  CAS  Google Scholar 

  6. Ceccarelli F, Botticelli A, Gelibter AJ, Leccese I, Lucchetti R, Cortesi E, Valesini G, Marchetti P, Conti F. ‘Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation’ by Braaten et al: another point of view. Ann Rheum Dis. 2020. https://doi.org/10.1136/annrheumdis-2019-216867.

  7. Cappelli LC, Dorak MT, Bettinotti MP, Bingham CO, Shah AA. Association of HLA-DRB1 shared epitope alleles and immune checkpoint inhibitor-induced inflammatory arthritis. Rheumatology. 2019;58:476–80.

    Article  CAS  Google Scholar 

  8. Sakakida T, Ishikawa T, Chihara Y, Harita S, Uchino J, Tabuchi Y, Komori S, Asai J, Narukawa T, Arai A, Tsunezuka H, Kosuga T, Konishi H, Moriguchi M, Yasuda H, Hongo F, Inoue M, Hirano S, Ukimura O, Itoh Y, Taguchi T, Takayama K. Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies. Clin Transl Oncol. 2020;22:919–27.

    Article  CAS  Google Scholar 

  9. Grygiel-Górniak B, Rogacka N, Puszczewicz M. Antinuclear antibodies in healthy people and non-rheumatic diseases—diagnostic and clinical implications. Reumatologia. 2018;56:243–8.

    Article  Google Scholar 

  10. Yoneshima Y, Tanaka K, Shiraishi Y, Hata K, Watanabe H, Harada T, Otsubo K, Iwama E, Inoue H, Masuda S, Nakanishi Y, Okamoto I. Safety and efficacy of PD-1 inhibitors in non-small cell lung cancer patients positive for antinuclear antibodies. Lung Cancer. 2019;130:5–9.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Reumatologia, Dipartimento di Scienze Cliniche, Internistiche, Anestesiologiche e Cardiovascolari, Sapienza Università di Roma, Viale del Policlinico 155, 00161, Rome, Italy

    F. Ceccarelli, F. Natalucci, G. Olivieri, C. Alessandri & F. Conti

  2. Medical Oncology Unit B, Policlinico Umberto I, Rome, Italy

    A. Botticelli, A. Cirillo & P. Marchetti

Authors
  1. F. Ceccarelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Botticelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Natalucci
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Olivieri
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Cirillo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C. Alessandri
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. P. Marchetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. F. Conti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F. Ceccarelli.

Ethics declarations

Conflict of interest

Nothing to declare.

Ethical approval

The ethical committee approved the study.

Research involving human and animal rights

Description of a case.

Informed consent

Informed consent is not required because the provided information are anonymous.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ceccarelli, F., Botticelli, A., Natalucci, F. et al. Immune checkpoint inhibitors and pre-existing antinuclear antibodies: the rheumatologist point of view. Clin Transl Oncol 23, 1961–1962 (2021). https://doi.org/10.1007/s12094-021-02584-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-021-02584-y

Keywords

Search

Navigation